Connect Biopharma Holdings Ltd CNTB
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Connect Biopharma Holdings Ltd (CNTB) is a healthcare company listed in the US with a market value of about $43M. In the twelve months to June 30, 2026 it had revenue of $3M and net income of -$69M, a net margin of -2336.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -54%.
About Connect Biopharma Holdings
Connect Biopharma Holdings is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 5 years in our data. It spends 59059% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $3M | $64000 | $26M | $0 | — | — |
| Net income | -$69M | -$55M | -$16M | -$62M | -$118M | -$202M |
| Free cash flow | -$61M | -$52M | -$24M | -$48M | -$106M | -$88M |
| EPS (diluted) | $-1.19 | $-0.88 | $-0.25 | $-0.99 | $-1.88 | $-3.21 |
| Net margin | -2336.3% | -86687.5% | -60.0% | — | — | — |
| ROIC | — | -107.5% | -19.2% | -53.5% | -59.5% | -28.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Connect Biopharma Holdings pay a dividend?
Not currently.
Is Connect Biopharma Holdings a good stock to buy?
We do not give buy or sell advice. Connect Biopharma Holdings scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.